. 2021 Jan 26;6(3):218–224. doi: 10.1016/S2468-1253(21)00024-8

Table.

Overview of published phase 3 SARS-CoV-2 vaccination studies

	Pfizer/BioNTech⁸	Oxford/AstraZeneca⁹	Moderna¹⁰
Name	BNT162b2	ChAdOx1 nCoV-19	mRNA-1273
Dosing schedule	2 doses, 21 days apart^*	2 doses, 28 days apart^*	2 doses, 28 days apart^*
Mechanism	mRNA encoding a genetically modified SARS-CoV-2 spike protein	Non-replicating adenovirus vector, containing SARS-CoV-2 spike protein	mRNA encoding a genetically modified SARS-CoV-2 spike protein
Storage (long term)	−80°C to −60°C	+2°C to +8°C	−20°C
Reported efficacy	95%	70%^†	94·5%
Safety	No serious concerns. Two anaphylactoid reactions since MHRA approval and roll-out	No serious concerns	No serious concerns
UK MHRA approval	Emergency approval granted Dec 2, 2020	Emergency approval granted Dec 30, 2020	Emergency approval granted Jan 8, 2021

In the UK, the Joint Committee on Vaccination and Immunisation has advised that the second dose of BNT162b2 can be given between 3 and 12 weeks after the first dose and the second dose of both mRNA-1273 and ChAdOx1 nCoV-19 can be given between 4 and 12 weeks after the first dose.

^†

Pooled data from two trials: 62% efficacy in one study and 90% in another study in which first vaccination was given at half dose.